Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia.
Rekhi G, Alphs L, Ang MS, Lee J.
Eur Neuropsychopharmacol. 2019 Dec;29(12):1433-1441. doi: 10.1016/j.euroneuro.2019.10.009. Epub 2019 Nov 22.
PMID:31761524
Movement initiation and preparation in subjects with schizophrenia - The amplitude of the readiness potential as a biological marker for negative symptom severity.
Vöckel J, Thiemann U, Weisbrod M, Schröder J, Resch F, Klein C, Bender S.
Schizophr Res. 2023 Oct;260:3-11. doi: 10.1016/j.schres.2023.07.012. Epub 2023 Aug 3.
Cochrane Database Syst Rev. 2015 Jan 25;1(1):CD010653. doi: 10.1002/14651858.CD010653.pub2.
PMID:25879096
Impact of early negative symptom patterns on the long-term outcomes of patients with first-episode schizophrenia-spectrum disorders: A 12-year follow up study.
Suen YN, Pang SWT, Cheung C, Wong TY, Hui LMC, Lee HME, Chang WC, Chen YHE, Chan SKW.
Psychiatry Res. 2023 May;323:115180. doi: 10.1016/j.psychres.2023.115180. Epub 2023 Mar 24.